Assessment of Immune Response After Vaccination Against COVID-19 in Patients Treated With Renal Replacement Therapy (COViNEPH-1)
Multi Center Study to Assess the Humoral and Cellular Response After Vaccination Against COVID-19 in Patients Treated With Renal Replacement Therapy
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
- Venous blood samples will be collected at seven-time points: before dose 1 of vaccine, 21 days after dose 1, within 14-21 days after dose 2 and 3,6,9,12 months after vaccination. From the volume of about 8 ml of the patient's peripheral blood, a fraction of PBMC (peripheral blood mononuclear cells) will be isolated, which in the first stage of the study will be frozen in nitrogen. To generate serum, blood samples were centrifuged at room temperature at 2500 RPM for 10 minutes, aliquoted, frozen in -70˚C, and stored until use.
- The level of antibodies against the SARS-CoV-2 nucleocapsid (N) antigen will be detected in serum using the Abbot Architect™SARS-CoV-2 IgG test.
- The level of neutralizing IgG and IgA antibodies against the SARS-CoV (S1 and S2 subunits) (S) will be detected in serum using the DiaSorin LIAISON®SARS-CoV-2 S1/S2 IgG serology COVID-19 S-Protein (S1RBD) Human IgA ELISA Kit respectively.
- The cellular component of the immune response will be tested using the ELISPOT method, which involves testing the amount of INF-γ and IL-2 released from leukocyte cells.
- The grading scales for side effects (the same as in the pivotal trial) used in this study were derived from the FDA Center for Biologics Evaluation and Research (CBER) guidelines on toxicity grading scales for healthy adult volunteers enrolled in preventive vaccine clinical trials.
- All medical data of patients from all groups will be extracted from their medical records.
Tipo de estudio
Tipo de estudio
Inscripción (Anticipado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Leszek Tylicki, MD PhD
- Número de teléfono: 0048583492830
- Correo electrónico: leszek.tylicki@gumed.edu.pl
Ubicaciones de estudio
-
-
-
Gdańsk, Polonia
- Reclutamiento
- 7th Naval Hospital in Gdansk
-
Contacto:
- Ewelina Puchalska-Reglińska, MD
- Correo electrónico: e.puchalska@7szmw.pl
-
Gdynia, Polonia
- Reclutamiento
- NZOZ Diaverum Gdynia
-
Contacto:
- Waldemar Ślizień, MD PhD
- Correo electrónico: waldemar.slizien@diaverum.com
-
Gdynia, Polonia
- Reclutamiento
- The University Centre of Maritime and Tropical Medicine in Gdynia
-
Contacto:
- Marcin Renke, MD PhD
- Correo electrónico: mrenke@gumed.edu.pl
-
-
Pomorskie
-
Gdansk, Pomorskie, Polonia, 80-211
- Reclutamiento
- Medical University of Gdańsk
-
Contacto:
- Leszek Tylicki, MD PhD
- Número de teléfono: +48583492830
- Correo electrónico: leszek.tylicki@gumed.edu.pl
-
Sub-Investigador:
- Bogdan P Biedunkiewicz, MD PhD
-
Sub-Investigador:
- Alicja Dębska-Ślizień, MD PhD
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients will be recruited in:
- Department of Nephrology Transplantology and Internal Medicine, Medical University of Gdansk.
- NZOZ Diaverum Hemodialysis Unit in Gdynia.
- The University Centre of Maritime and Tropical Medicine in Gdynia
- 7th Naval Hospital in Gdansk
Descripción
Inclusion Criteria:
- patients on chronic dialysis (hemodialysis or peritoneal dialysis) for at least 1 months and had received vaccination with mRNA vaccine BNT162b2 (BionTech/Pfizer Comirnaty) with a 3-week interval between first and second doses.
Exclusion Criteria:
- (-)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Hemodialyzed patients
Hemodialyzed patients vaccinated with BNT162b2 - mRNA vaccine against COVID-19
|
The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials.
Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination.
Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
|
|
Patients treated with peritoneal dialysis
Patients treated with peritoneal dialysis vaccinated with BNT162b2 - mRNA vaccine against COVID-19
|
The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials.
Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination.
Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
|
|
Patients without chronic kidney disease
Patients without chronic kidney disease vaccinated with mRNA BNT162b2 - vaccine against COVID-19
|
The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials.
Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination.
Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
|
|
Kidney transplant recipients
Kidney transplant recipients vaccinated with mRNA vaccine against COVID-19
|
The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials.
Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination.
Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Humoral immune response
Periodo de tiempo: 12 months (7 time points)
|
Neutralizing IgG antibodies against the SARS-CoV (S1 and S2 subunits) (S)
|
12 months (7 time points)
|
|
Humoral immune response
Periodo de tiempo: 12 months (7 time points)
|
Neutralizing IgA antibodies against the SARS-CoV (S1 and S2 subunits) (S)
|
12 months (7 time points)
|
|
The cellular immune response.
Periodo de tiempo: 12 months (7 time points)
|
Testing the amount of INF-γ and IL- 2 released from leukocyte cells in response to stimulation with S proteins
|
12 months (7 time points)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Solicited and unsolicited local and systemic reactogenicity
Periodo de tiempo: Until 1 month after the second dose
|
Solicited common and expected adverse reactions shortly following vaccination (reactogenicity), use of antipyretic or pain medications and unsolicited adverse events and serious adverse events, i.e. those reported by the participants without prompts from the medical staff or observed by their physicians through 1 month after the second dose.
|
Until 1 month after the second dose
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Anticipado)
Finalización primaria
Finalización del estudio (Anticipado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones por coronavirus
- Infecciones por coronaviridae
- Infecciones por Nidovirales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones del Tracto Respiratorio
- Enfermedades de las vías respiratorias
- Neumonía Viral
- Neumonía
- Enfermedades pulmonares
- Enfermedades Renales
- Enfermedades urológicas
- Insuficiencia Renal Crónica
- COVID-19
- Insuficiencia Renal Crónica
- Insuficiencia renal
- Efectos fisiológicos de las drogas
- Agentes del sistema nervioso periférico
- Agentes del sistema sensorial
- Analgésicos
- Antipiréticos
Otros números de identificación del estudio
Otros números de identificación del estudio
- COViNEPH-1
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .